ADAR1 Capital Management LLC Boosts Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

ADAR1 Capital Management LLC raised its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 114.4% during the 4th quarter, Holdings Channel reports. The firm owned 647,960 shares of the biotechnology company’s stock after purchasing an additional 345,748 shares during the quarter. ADAR1 Capital Management LLC’s holdings in Aldeyra Therapeutics were worth $3,233,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Raymond James Financial Inc. acquired a new position in shares of Aldeyra Therapeutics in the fourth quarter worth $3,628,000. Jacobs Levy Equity Management Inc. raised its stake in Aldeyra Therapeutics by 163.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after purchasing an additional 295,864 shares during the last quarter. Kennondale Capital Management LLC purchased a new position in Aldeyra Therapeutics in the 4th quarter valued at about $755,000. Trexquant Investment LP boosted its stake in shares of Aldeyra Therapeutics by 895.5% during the 4th quarter. Trexquant Investment LP now owns 114,480 shares of the biotechnology company’s stock worth $571,000 after purchasing an additional 102,980 shares during the last quarter. Finally, Barclays PLC grew its holdings in shares of Aldeyra Therapeutics by 280.1% during the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock worth $353,000 after buying an additional 48,313 shares in the last quarter. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research note on Friday.

Aldeyra Therapeutics Trading Up 33.1 %

Shares of ALDX opened at $1.89 on Monday. Aldeyra Therapeutics, Inc has a fifty-two week low of $1.14 and a fifty-two week high of $7.20. The company’s fifty day moving average is $6.00 and its two-hundred day moving average is $5.44. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30). Equities analysts predict that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current fiscal year.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.